Gain Therapeutics

It's the reader's choice. It's 𝙮𝙤𝙪𝙧 choice. 🫵 But that doesn't make picking a winner any easier. Join us in recognizing and celebrating the incredible people, programs, and organizations making impact across the regon with your 𝘃𝗼𝘁𝗲 today and every day [between now and 11:59 p.m. EST Friday, December 13, 2024]. ➡ https://lnkd.in/er8piHHE There is no shortage of incredible finalists to choose from. Like...  🏆 Gene Mack and Gain Therapeutics 🏆 Raymond Cypess and ATCC 🏆 Atul Saran and IntegerBio 🏆 Robert Ross and Clasp Therapeutics 🏆 Michael Feld and BD 🏆 Yolanda L. Langhorne, EdD and the UMB CURE Scholars Program 🏆 Luis Alvarez and Theradaptive 🏆 Patrick Hanley, Ph.D. and Children's National Hospital 🏆 Chad Clark and Precision For Medicine 🏆 Howard Carolan and CoapTech 🏆 Jesse Christopher and Longeviti Neuro Solutions 🏆 Nicanor Aquino and Montgomery College 🏆 Bert Vogelstein and The Johns Hopkins University 🏆 Debra Hettleman and Building STEPS 🏆 Ned McCoy and Civica Rx 𝘼𝙣𝙙 𝙨𝙤 𝙢𝙖𝙣𝙮 𝙢𝙤𝙧𝙚... 👏 Stay tuned over the coming weeks as we celebrate our finalists and their incredible impact. ➕ Plus, a huge 𝙏𝙃𝘼𝙉𝙆 𝙔𝙊𝙐 to our partners who made this year's Awards possible: US Pharmacopeia (USP), Avantor, MilliporeSigma, Blackbird Laboratories, Integral Molecular, and Life Science Wealth. #leadership #innovation #community #workforce #lifesciences #maryland #virginia

Tune in to a thoughtful conversation from #SfN24 between our very own Senior Vice President of Research Joanne Taylor and Megan Thomas from Drug Discovery World. Listen here: https://lnkd.in/gGYkv9_n

Oral GT-02287 seen to safely enter brain in early #Parkinson's clinical trial GCase activity in dried blood spots increased approximately 53% in healthy volunteers. Phase 1b clinical trial expected to initiate by EOY 2024. https://lnkd.in/edscRnNH

I had the pleasure of speaking with Gene Mack, Interim CEO & CFO of Gain Therapeutics. Gene brings a unique perspective from his time on Wall Street, shedding light on how biotech financing has evolved. In our conversation, we dive deep into Gain Therapeutics' approach to neurodegenerative diseases, especially their work on Parkinson's. Gene shares his insights on the critical shift from simply managing symptoms to addressing the underlying biology of these diseases—an approach that holds promise for patients and the industry alike.

Gain Therapeutics reports financial results for Third Quarter 2024 and provides corporate update. “The third quarter of 2024 marked substantial progress for Gain and the development of GT-02287...Data from our Phase 1 study for GT-02287 presented recently at both the International Congress of Parkinson’s Disease and Movement Disorders and the Michael J Fox Foundation Annual Parkinson’s Disease Therapeutics Conference demonstrated target engagement with a 53% increase in GCase activity along with favorable safety and tolerability in healthy volunteers...We also submitted the pre-IND package for our upcoming meeting with the FDA scheduled before year end to facilitate the Phase 2 expansion of our clinical development plans for GT-02287 in 2025, moving us significantly closer to developing the first disease-modifying therapy for patients with Parkinson’s disease,” said Gene Mack, Interim CEO and CFO of Gain Therapeutics. Read the full press release here: https://lnkd.in/gebkrChA

Early identification could allow the treatment of patients even before symptoms occur, which is the endgame for a disease-modifying approach such as our drug candidate GT-02287. #neurodegeneration #parkinsons #neurosciences https://lnkd.in/eJ7M9jYn

Listen in to an insightful conversation between Gain CFO and Interim CEO Gene Mack and Rahul Chaturvedi in the latest episode of Biotech2050. Click below to tune in and learn more about Gene's career path, Gain's lead drug candidate GT-02287, and the challenges of today's biotech landscape. #Biotech2050 website: https://lnkd.in/gdxMtMh4 Soundcloud: https://lnkd.in/gbEZ_2MV Apple Podcasts: https://lnkd.in/gP2SDrzv #BiotechInnovation #ParkinsonsResearch #Neuroscience #GainTherapeutics 

Hearing loss is a big risk factor for developing Parkinson's: Study https://lnkd.in/e9YiXu2Z

Gain Therapeutics Presents Data at the 36ᵗʰ EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics Demonstrating Identification of Allosteric Inhibitors Targeting DDR2 Read the full press release here: https://lnkd.in/gPr9QRS4

Gain Therapeutics Presents Preclinical GT-02287 Data at #SfN24. “The preservation of motor and cognitive improvement in animal models of Parkinson’s disease associated with GT-02287 after its discontinuation coupled with the neuroprotective effects after delayed administration support the potential of GT-02287 to slow or stop the progression of Parkinson’s disease,” said Gene Mack, Interim CEO and CFO of Gain Therapeutics. “The potential of GCase as a therapeutic target beyond Parkinson’s Disease is an encouraging finding that we can incorporate into our future development plans for GT-02287.” Read the full press release here: https://lnkd.in/gj6QMFZ8